A Registry Study on Biomarkers of Pulmonary Embolism
- Conditions
- Pulmonary Embolism
- Registration Number
- NCT04118634
- Lead Sponsor
- Beijing Institute of Heart, Lung and Blood Vessel Diseases
- Brief Summary
The purpose of the study is to evaluate the value of biomarkers in the diagnosis and risk stratification of patients with suspected pulmonary embolism.
- Detailed Description
Management of patients with acute pulmonary embolism is a serious problem. The rapid and accurate diagnosis and risk stratification of these patients is an important unmet clinical need. The aim of the study is to evaluate the value of biomarkers, alone or in combination, in the diagnosis and risk stratification of patients with suspected pulmonary embolism presenting to the emergency department.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 480
- Patient aged ≥ 18 years that presents to an emergency department
- With suspected PE defined as new onset of or worsening of shortness of breath or chest pain
- Hemodynamic instability
- Life expectancy less than 3 months
- First symptoms 15 day or more before inclusion
- Inability to the follow-up visits
- Therapeutic anticoagulation for any indication
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Area under the ROC curve of biomarkers for the diagnosis of PE 2 years The ROC curve will be built, the area under the curve will be calculated with its confidence interval.
PE related death 7 days Number of PE related death
- Secondary Outcome Measures
Name Time Method Symptomatic recurrent venous thromboembolic events 2 years Number of symptomatic recurrent venous thromboembolic event
Trial Locations
- Locations (1)
Beijing Anzhen Hospital
🇨🇳Beijing, Beijing, China